vimarsana.com
Home
Live Updates
Purple Biotech Issues Letter to Shareholders : vimarsana.com
Purple Biotech Issues Letter to Shareholders
REHOVOT, Israel, Feb. 04, 2022 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by overcoming tumor
Related Keywords
United States ,
Israel ,
Rehovot ,
Hamerkaz ,
Texas ,
American ,
Gil Efron ,
Robert Gagnon ,
Bristol Myers Squibb ,
Suzana Nahum Zilberberg ,
Exchange Commission ,
Department Of Cancer Biology ,
University Of Texas Md Anderson Cancer Center ,
Company Contact ,
Purple Biotech Ltd ,
Drug Administration ,
Purple Biotech ,
Chief Executive Officer ,
Isaac Israel ,
Cancer Center ,
Menashe Bar Eli ,
Cancer Biology ,
Ori Hershkovitz ,
Fabien Sebille ,
Chief Business ,
Chief Executive Officer Purple ,
Looking Statements ,
Safe Harbor ,
Private Securities Litigation Reform Act ,
Annual Report ,
Registration Statements ,
Money ,
Ational ,
vimarsana.com © 2020. All Rights Reserved.